AAPGAscentage Pharma Group Inc.Signing up patients
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 75 (planned)
- Started
- Dec 28, 2021
- Main results expected
- Dec 2026
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to 9 months after the last subject enrolled.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05147467 · record last updated 2026-03-27 · checked 2026-11-09 15:47 UTC